Abstract Number: 0205 • ACR Convergence 2024
Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Background/Purpose: A growing body of evidence highlights a link between rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE)…Abstract Number: 0540 • ACR Convergence 2024
Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis
Background/Purpose: Patients with axial spondyloarthritis (axSpA) have a heightened risk of cardiovascular morbidity and mortality. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line treatment for axSpA,…Abstract Number: 0857 • ACR Convergence 2024
Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study
Background/Purpose: Immunosuppressive therapy, including Tumor necrosis factor inhibitors (TNFi), is commonly used in the treatment of various inflammatory conditions, including extracardiac sarcoidosis. However, the use…Abstract Number: 1347 • ACR Convergence 2024
Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular (CV) mortality, linked to systemic inflammation and the presence of associated CV risk factors.…Abstract Number: 1719 • ACR Convergence 2024
Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Our work presented previously suggests recent GC use (up to 2 years prior…Abstract Number: 2230 • ACR Convergence 2024
Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis
Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…Abstract Number: 0215 • ACR Convergence 2024
BP Connect Improves Follow-up of High Blood Pressure in Urban Rheumatology and Non-Rheumatology Clinics
Background/Purpose: Hypertension accounts for >54% of modifiable cardiovascular disease (CVD) risk and although 49% of US outpatient visits occur in specialty clinics, only 10% of…Abstract Number: 0598 • ACR Convergence 2024
Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Background/Purpose: Psoriatic arthritis (PsA) is associated with metabolic and cardiovascular disease. Studies have suggested that treatment with apremilast is associated with weight loss and other…Abstract Number: 0870 • ACR Convergence 2024
The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use
Background/Purpose: The impact of body mass index (BMI) as a surrogate of body fat content on cardiovascular (CV) risk in rheumatoid arthritis (RA) is unclear.…Abstract Number: 1350 • ACR Convergence 2024
Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting the joints that is associated with increased cardiovascular risk. Environmental factors play a crucial role…Abstract Number: 1723 • ACR Convergence 2024
Clustering Analysis with Unsupervised Machine Learning Process to Phenotype the Cardiovascular Risk of Patients with Rheumatoid Arthritis Beyond the 10-year Prediction Algorithm
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased cardiovascular (CV) risk, but traditional CV risk factors and available 10-year CV risk estimation models may not…Abstract Number: 2235 • ACR Convergence 2024
The Updated PREVENT (Predicting Risk of CVD EVENTs) Algorithm Is Not Able to Indicate Subclinical Coronary or Carotid Atherosclerosis Better Than the Traditional Pooled Cohort Equations in Rheumatoid Arthritis
Background/Purpose: Patients with RA are at increased risk of atherosclerotic cardiovascular disease (ASCVD), yet traditional 10-year CVD risk calculators—such as the 2013 Pooled Cohort Equations…Abstract Number: 2623 • ACR Convergence 2024
Cardiovascular Health Is Suboptimal in Most Patients with Juvenile-Onset Lupus and Dermatomyositis: Baseline Visit Findings from the Lupus Erythematous and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) are associated with premature cardiovascular disease (CVD). The American Heart Association (AHA) cardiovascular health (CVH) score is the…Abstract Number: 0229 • ACR Convergence 2024
An Early Inflammatory Cardiac Phenotype and Association with Future Coronary Plaque Burden in Rheumatoid Arthritis
Background/Purpose: Patients with RA are at increased risk of cardiovascular disease (CVD) compared to the general population. In a prior study of RA patients with…
- 1
- 2
- 3
- …
- 31
- Next Page »